How RAREready helps

Practical EU JCA readiness for rare-disease teams

JCA began in 2025. Most rare disease teams are not yet working through it directly — but many are watching the early oncology and ATMP assessments carefully, and beginning to ask what they will need to have in place when their own programmes reach that point.

That is exactly the right moment to be asking the question – and the right moment to start building the internal conditions to act on JCA thinking effectively.

This is where RAREready helps.

What we do

We work with cross-functional rare disease teams to make JCA thinking visible, clearly owned and usable at the moments when decisions are actually being shaped.

RAREready™ Asset-level working sessions 

For teams who want to connect JCA thinking to real decisions on live assets now

RAREready™ JCA decision aid 

For teams who want a practical tool that works inside existing processes

Written in plain language and designed to sit inside existing conversations rather than add to them. It makes explicit what questions are worth asking at each stage, what good looks like, and who is best placed to raise and act on each point.

RAREready™ Organisational playbook

For teams building a broader, lasting internal capability around JCA

Next step
A 20-minute conversation is usually enough to confirm relevance, timing and the right place to start.